Publicaciones (108)


  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities

    European urology oncology, Vol. 5, Núm. 6, pp. 726-731

  3. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

    European Urology, Vol. 82, Núm. 3, pp. 283-292

  4. Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

    Oncotarget, Vol. 13, pp. 237-256

  5. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer

    Cancers, Vol. 14, Núm. 2

  6. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502

  7. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373

  8. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

    Critical Reviews in Oncology/Hematology, Vol. 174

  9. The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review

    Precision Cancer Medicine, Vol. 5